Invea Therapeutics, Inc filed a Form D with the Securities and Exchange Commission on 2025-12-10.
Invea Therapeutics, Inc filed a Form D notice of an exempt securities offering with the SEC on December 10, 2025. The filing reports $120K sold. Its industry group is Biotechnology. It names Krishnan Nandabalan (Chief Executive Officer and Chairman), Aman Kant (President), Michael Aiello (Chief Financial Officer) (SEC Form D, December 10, 2025).
Sell to companies like Invea Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Invea Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Invea Therapeutics, Inc, from the filings we hold.
Biotechnology raises by companies based in Connecticut, filed within 90 days of this one, largest first.
Get an email when Invea Therapeutics, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Invea Therapeutics, Inc raises, hires or launches. No email unless you switch it on.
Watch Invea Therapeutics, Inc →Get the full cited report on Invea Therapeutics, Inc
What the filing shows about Invea Therapeutics, Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Invea Therapeutics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Invea Therapeutics, Inc See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $120K, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Krishnan Nandabalan is named as Chief Executive Officer and Chairman on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Aman Kant is named as President on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Michael Aiello is named as Chief Financial Officer on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Salvatore Alesci is named as Chief Scientific Officer on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Shunichiro "Steve" Okada is named as Chief Medical Officer on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
Kerrie Brady is named as Director on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
Stephen Doberstein is named as Director on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
Demetrios Kydonieus is named as Director on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
Jonathan Zalevsky is named as Director on the Form D that Invea Therapeutics, Inc filed with the SEC on 10 December 2025, one of 9 people that filing names.
9 people named on the filing — 5 holding an executive role and 4 as directors only.
Named as of the 2025-12-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Invea Therapeutics, Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Invea Therapeutics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Invea Therapeutics, Inc covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Invea Therapeutics, IncYou get an alert in MentionFox the next time this company shows up.
If you're behind Invea Therapeutics, Inc: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Invea Therapeutics, Inc. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/invea-therapeutics-inc-form-d-25000001